Is Adagene Inc. (ADAG) Overvalued?
We dive into why Adagene Inc. (ADAG) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Commentary & Analysis
Why Adagene Inc.’s (ADAG) Stock Is Down 5.87%
As of Friday, July 17, Adagene Inc.’s ADAG share price has dipped by 5.87%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adagene Inc.’s (ADAG) Stock Is Up 5.22%
As of Thursday, July 09, Adagene Inc.’s ADAG share price has surged by 5.22%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Adagene Inc.’s (ADAG) Stock Is Down 9.62%
As of Monday, July 06, Adagene Inc.’s ADAG share price has dipped by 9.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Adagene Inc.’s (ADAG) Stock Is Down 11.41%
As of Monday, July 06, Adagene Inc.’s ADAG share price has dipped by 11.41%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ADAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $258.5 | $298.4 | 29% |
|
| Shares Out (Mil) | 56.6 | 54.0 | 50% |
|
| Institutional Ownership | 79.6% | 93.1% | 48% |
|
| Float (Mil) | 42.2 | 41.4 | 43% |
|
| Beta | 0.57 | 0.94 | 33% |
|
| Avg Daily Volume (000s) | 255 | 504 | 49% |
|
| Price Change (52-week) |
63.8% | 62.0% | 85% |
|
| Growth | ADAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 61.5% | 14.0% | 97% |
|
| Net Income (5yr) | 16.1% | (10.0%) | 66% |
|
| EPS (5yr) | 35.4% | 16.0% | 85 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 29.9% | (15.6%) | 86% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ADAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($21) | ($43) | 24% |
|
| EPS (TTM) | ($0.395) | ($1.400) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($32) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $65 | $2 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $165 | $186 | 25% |
|
| Valuation | ADAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.89 | 2.89 | 63% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ADAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.6% | 96% |
|
| Net Margin | (220.8%) | (75.3%) | 4% |
|
| ROA | (20.5%) | (47.6%) | 20% |
|
| ROE | (32.2%) | (55.0%) | 19% |
|
| Liabilities to Assets | 20.6% | 29.5% | 14% |
|
| F-Score | 3 | 3 | 18% |
|
Adagene Inc. did not pass any screens on 8/26/2026.
